Transfer of Frozen Embryos in Natural Cycle: Evaluation of Impact of Spontaneous Versus HCG-triggered Ovulation on Pregnancy Rate
TECNAT
2 other identifiers
interventional
103
1 country
2
Brief Summary
The purpose of the study is to evaluated whether there is a difference in pregnancy rate when transferring frozen embryos between patietns having spontaneously ovulated versus those triggered to voulate with HCG.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2018
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 5, 2018
CompletedFirst Posted
Study publicly available on registry
February 9, 2018
CompletedStudy Start
First participant enrolled
March 7, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 29, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2022
CompletedDecember 4, 2025
June 1, 2022
3.3 years
February 5, 2018
November 26, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Pregnancy rate after transfer of frozen embryos at day 14 between groups
Yes/no; Blood ßHCG \> 100UI/L
Day 14
Secondary Outcomes (7)
Pregnancy rate at week 12
Week 12
Miscarriage rate within first 12 weeks
Week 12
Live birth
At delivery, maximum week 42
Pregnancy term
At delivery, maximum week 42
Birth weight
At delivery, maximum week 42
- +2 more secondary outcomes
Study Arms (2)
human chorionic gonadotropin (HCG)
OTHEROvulation triggered using HCG: choriogonadotropin alpha (Ovitrelle, Merck Serono), 250 μg/0.5ml
spontaneous
NO INTERVENTIONInterventions
250 μg/0.5ml choriogonadotropine alpha, Ovitrelle, Merck Serono
Eligibility Criteria
You may qualify if:
- The patient must have given their free and informed consent and signed the consent form
- The patient must be a member or beneficiary of a health insurance plan
- The patient is aged between 18 and 40
- Patient has regular cycles and classified as 'easy' for transfer of a frozen embryo at blastocyste stage (vitrification day 5)
You may not qualify if:
- The subject refuses to sign the consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Patient using donated oocytes
- Necessity of pre-implantation diagnosis
- Patients with stage 3 or 4 endometriosis or adenomyosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
CHU Arnaud de Villeneuve
Montpellier, 34295, France
CHU Nimes
Nîmes, 30029, France
Related Publications (1)
Ranisavljevic N, Bonneau M, Rougier N, Hamamah S, Anahory T, Serand C, Huberlant S. Ovulation trigger versus spontaneous luteinizing hormone surge on live birth rate after frozen embryo transfer in a natural cycle: a randomized controlled trial. Fertil Steril. 2025 Apr;123(4):718-720. doi: 10.1016/j.fertnstert.2024.10.021. Epub 2024 Oct 19. No abstract available.
PMID: 39433204RESULT
Study Officials
- PRINCIPAL INVESTIGATOR
Stéphanie Huberlant
CHU Nimes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 5, 2018
First Posted
February 9, 2018
Study Start
March 7, 2018
Primary Completion
June 29, 2021
Study Completion
February 1, 2022
Last Updated
December 4, 2025
Record last verified: 2022-06